High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 1583319.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment with aminoglycosides is known to cause irreversible hearing loss, typically affecting higher-frequency hearing first and progressing to lower frequencies. Standardized methodology has not been developed for early detection of ototoxicity. Serial conventional (0.25-8 kHz) and high-frequency (9-20 kHz) hearing threshold monitoring was done prospectively in 53 hospitalized patients administered aminoglycosides. Hearing loss occurred in 47% of the ears studied, with hearing loss first appearing in the high-frequency range in 71% of ears showing change. Analysis of data on an individual basis revealed a five-frequency range most susceptible to initial ototoxicity. Testing only this range would have resulted in early identification of 82% of ears showing change. Results confirm the critical need for serial auditory threshold monitoring encompassing high frequencies in patients receiving aminoglycosides. A shortened five-frequency monitoring protocol is presented and suggested for use with patients unable to tolerate lengthy audiometric testing procedures.
Medical subject headings
- Anti-Bacterial Agents
- Hearing Loss
- Hearing Loss, Bilateral